CRP and cancer: A 2022 prospective cohort study by Japan’s National Cancer Center demonstrated that COX-2, as a mechanistic inflammatory biomarker, enhances risk stratification for tumor initiation when integrated with traditional markers like CRP, providing incremental value beyond standalone CRP assessment [347].